Company Overview and News
Energy producers have flocked to the prolific Permian Basin boosting demand for takeaway capacity and creating serious bottlenecks.
ETP.PRC DCP CJ XEC KMI.WS CRLFF DVN REN PE CXO SCAZP EPD ENB MPC ANDV AXAS CRZO AREX KMI.PRA KMI RSPP PAA MMP JAG SNZYP KMR CVB SN CDEV NBL MTDR SM BWP HKRCP DCP.PRB HK.WS ESTE PSXP SRE.PRA ETP DPM SRE CVX LPI HK TRGP KMRFZ
Merger and acquisition activities across the globe hit record highs in the first half of 2018 driven by growing ambition of American companies. According to the latest Thomson Reuters Deals Intelligence data, global mergers and acquisitions totaled more than $2.5 trillion, up 64% from the year-ago level and marked the strongest year-to-date period since records began in 1980. With this rise, the mergers are on track to surpass $5 trillion in 2018, which would top 2015, the highest yearly total on record (read: How to Play the Surge in Global M&A With ETFs).
FOX TWX MRGR CI COL ANDV TWC FOXA
If you're interested in broad exposure to the Mid Cap Value segment of the US equity market, look no further than the iShares Morningstar Mid-Cap Value ETF (JKI - Free Report) , a passively managed exchange traded fund launched on 06/28/2004.
IWS VOE FITB JKI ANDV ICHR FITBI
Andeavor (ANDV - Free Report) recently announced its intention of constructing a new terminal for the refined products at the Mexican state-run electric utility, Comisión Federal de Electricidad’s (“CFE”) Rosarito storage facility, located in the Baja California state. Per the terms of Andeavor’s deal with CFE’s subsidiary, CFEnergía, the former will take lease of the site for a long-term, where it plans to build the facility.
DK HSC UNP HFC ABM MPC ANDV
SAN ANTONIO, June 06, 2018 (GLOBE NEWSWIRE) -- Andeavor (NYSE:ANDV) anunció el día de hoy planes para construir una terminal de productos refinados en las instalaciones de almacenamiento de CFE en Rosarito, Baja California. Bajo los términos del acuerdo Andeavor firmará un contrato de arrendamiento de largo plazo por los terrenos con CFE y construirá y operará las instalaciones, lo cual representa una inversión cercana a los $100 millones de dólares.
The May MLP Monthly Report can be found here offering insights on MLP industry news, the asset class’s performance, yields, valuations, and fundamental drivers.
EEQ SNSR MLPA AND LIT BFIT GXG SIL KRMA GXF CHII MPC ANDV SEP ANDX EV ACTX CHIE WPZ GOEX FINX CHIX EEP SRET MPLX BOTZ CATH GURX GURI ALUM MILN CJHIQ URA BHI TCP LNGR COPX QQQC CQH GURU
Vertex Energy (VTNR) is, primarily, a used motor oil re-refiner. When crude oil prices fell in late 2014, it was pummeled and all but buried in the aftermath. The company quickly lost 90% of its value. The share price still reflects the challenges and trials. Vertex Energy has reported a net loss since its 2014 third quarter.
VTNR VLO MPC ANDV
12h - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
13h - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
as of ET